The U.S. District Court of the District of Columbia has ruled that the U.S. Food and Drug Administration can’t prevent natural health producers of Selenium from sharing their science behind the benefits of the supplement or force the manufacturers to add absurd or confusing disclaimers.
The ruling is considered by those in the natural health care industry to be a important precedent with far-reaching impact on food and dietary supplement producers and will allow the manufactures, nutritionalists and natural health care experts to share important studies, finds and science with the public on the health benefits uncovered.
The FDA cannot require that supplements be put through the same stringent, time-consuming and expensive investigations as pharmaceutical medicines before the science conducted on the supplements can be shared with the public.
As a result of the ruling, the public will not be deprived of important information when selecting and formulating their dietary supplement routine. As long as the science reported is correct, then the manufactures may publish a “qualified health claim,” written by the FDA about Selenium.
The FDA will allow the following qualified health claim about the important dietary mineral:
“Selenium may reduce the risk of bladder, colon, prostate, and thyroid cancers. Scientific evidence concerning this claim is inconclusive. Based on its review, FDA does not agree that selenium may reduce the risk of these cancers,” reports the FDA.
Though the U.S. federal court case only involved the reporting about Selenium, it is believed that this case will set a precedent that will affect all natural health supplements and is considered a victory by the alternative medicine community. Please click here for more information.
